Resistance Trends and Epidemiology of Acinetobacter Infections in Russia | CMAC

Resistance Trends and Epidemiology of Acinetobacter Infections in Russia

Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(2):96-105

Type
Journal article

Abstract

In vitro activity of 13 antimicrobials (amikacin, cefepime, cefoperazone, cefoperazone/sulbactam, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, levofloxacin, meropenem, piperacillin, piperacillin/tazobactam) against 464 Acinetobacter spp. strains, isolated in 30 departments of 20 Russian cities in 2002–2004, and 18 antimicrobials (listed above, plus doripenem, colistin, polymyxin B, netilmycin and ticarcillin/clavulanic acid) against 333 Acinetobacter spp. strains, isolated in 29 departments of 20 Russian cities in 2006–2008 was investigated. MBL and acquired CHDL detection among 67 carbapenem-resistant Acinetobacter spp. was performed. An increase of antimicrobial resistance to almost all classes of antimicrobials was found among nosocomial Acinetobacter spp. The most active drugs in 2006–2008 were: colistin, polymyxin B, imipenem, doripenem, cefoperazone/sulbactam, meropenem and netilmicin with 100, 99.7, 97.3, 92.7, 89.7, 85.5 and 78.2% susceptible strains, respectively. Twenty nosocomial infections cases caused by OXA-23- and OXA-58-producing Acinetobacter strains in different regions were detected.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared